Starting antihypertensives linked to hip fracture in elderly

NewsGuard 100/100 Score

By Sarah Guy, medwireNews Reporter

The risk for hip fractures among elderly individuals increases during the first 45 days after initiating antihypertensive medication, and significantly so for those who start angiotensin II converting-enzyme inhibitors and beta-adrenergic blockers, report Canadian researchers.

The study included data from over 300,000 newly treated community-dwelling elderly individuals aged a mean of 81 years, of whom 1,463 experienced hip fractures during the 450-day observation period.

"Caution should be exercised when antihypertensive treatment is begun in elderly patients to minimize their risk of the potentially devastating outcome of hip fractures," commented Debra Butt, from the University of Toronto, in a press statement.

The study findings were presented at The American Society for Bone and Mineral Research's 2012 Annual Meeting in Minneapolis, Minnesota.

While previous research indicates that starting antihypertensive treatment increases the risk for falls among the elderly, the risk for hip fractures is not known, maintain Butt and colleagues.

They linked data for hip fracture occurrences between April 2000 and March 2009 to data for 301,591 elderly patients (>80% female) who began treatment with thiazide diuretics, angiotensin II converting-enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, or beta-adrenergic blockers.

Participants had an overall 43% increased risk for hip fracture during the first 45 days after treatment initiation compared with (later) control periods, with a "generally consistent" association seen for each drug type, note the researchers.

However, the increase in risk for fracture was statistically significant for individuals taking two particular types of medication: at 53% for angiotensin II converting-enzyme inhibitors and 58% for beta-adrenergic blockers.

"This study is a start in an area where we have had few data," said Butt in her statement.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer